Ashland Global vs International Flavors & Fragrances: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ashland Global Holdings Inc (ASH)

Q3 202628 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

August 202628 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Latest28 Jul – 25 Sep 2026

▲3

Ashland's sale process advances as buyback and new product offset weak additives

Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

International Flavors & Fragrances Inc (IFF)

Q3 202614 Jul – 2 Oct 2026

▲3▼1

IFF's big portfolio overhaul and buyback drive the story

IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.
This is the biggest strategic event of the period, reshaping IFF's business and capital returns.
Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.
The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.
New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.
Product launches show IFF's innovation pipeline and support future revenue growth.
Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.
This reflects external validation of IFF's turnaround story and potential upside.

August 202614 Jul – 2 Oct 2026

▲3▼1

IFF's big portfolio overhaul and buyback drive the story

IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.
This is the biggest strategic event of the period, reshaping IFF's business and capital returns.
Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.
The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.
New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.
Product launches show IFF's innovation pipeline and support future revenue growth.
Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.
This reflects external validation of IFF's turnaround story and potential upside.

Latest14 Jul – 2 Oct 2026

▲3▼1

IFF's big portfolio overhaul and buyback drive the story

IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.
This is the biggest strategic event of the period, reshaping IFF's business and capital returns.
Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.
The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.
New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.
Product launches show IFF's innovation pipeline and support future revenue growth.
Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.
This reflects external validation of IFF's turnaround story and potential upside.